STOK
ストーク・セラピューティクス
STOK
ストーク・セラピューティクス
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript